What's wrong with using Xenon to climb Everest?
Reaching the top of the world and returning to London within a week without so much as stopping for a coffee in Kathmandu sounds like the stuff dreams are made of. But on 21 May 2025, four former members of the British special forces turned this dream into reality when they stood on the summit of Mount Everest four days and 11 hours after leaving the UK. Their secret was to inhale Xenon two weeks prior to the climb, a gas well known to anaesthetists, but so far unheard of in mountaineering.
'Although Xenon has worked well in clinical studies, it is very rarely used for patients in the UK. It is expensive and complex to administer with no significant benefits over established agents,' says Dr Mike Grocott, a professor of anaesthesia and critical care medicine at the University of Southampton.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
4 hours ago
- Daily Mirror
Holidaymakers to enjoy quicker flights after major UK airspace change
The changes will enable the largest redesign of UK airspace flight paths since it was first formed in the 1950s, when there were only around 200,000 flights per year Holidaymakers will enjoy quicker flights and fewer delays under major plans to open up new and more direct routes. The changes, laid in Parliament today, will enable the largest redesign of UK airspace flight paths since it was first formed in the 1950s, when there were only around 200,000 flights per year, compared to 2.7 million in 2024. The plans will help planes avoid having to circle in the sky while waiting to land, reducing delays and emissions per flight. Redesigned 'skyways' could also allow planes to climb quicker during take-off and descend more smoothly, reducing noise and air pollution for residents who live along flight routes. The new UK Airspace Design Service (UKADS), which will be delivered by NATS (En Route) plc, will be fully operational by the end of this year. It will initially focus on redesigning London's airspace. The Department for Transport said the redesign will support thousands of jobs in the aviation and tourism sectors. More than 100,000 extra jobs are expected to be created through the expansion at Heathrow alone. Over a longer timeframe, the UKADS could design routes that support flight paths for new and emerging technologies such as drones and flying taxis. In April, the Government announced £20million to launch new flight technologies, with ministers suggesting airborne taxis and commercial drones could take flight as soon as 2028. Last week marked a step towards the 2028 ambition after the first British flying taxi completed its first ever flight. Aviation Minister Mike Kane said: 'Redesigned 'skyways' will turbocharge growth in the aviation industry, not least by boosting airport expansion plans and supporting job creation, driving millions into the UK economy. 'Modernising our airspace is also one of the simplest ways to help reduce pollution from flying and will set the industry up for a long-term sustainable future.' Tim Alderslade, chief executive of Airlines UK, said: "Modernising UK airspace is long overdue and these changes will help to speed up a programme that will provide tangible reforms, from a reduction in delays, improved resilience and lower carbon emissions.'
The Sun
9 hours ago
- The Sun
Three-drug treatment combo ‘holds back aggressive breast cancer for a year'
A NEW triple threat drug combination could hold aggressive breast cancer at bay for an extra year, a trial found. Adding the medicine inavolisib to an already used pair of drugs delayed the need for chemotherapy by almost two years. 1 It prevented tumours from growing for an average of 17 months, compared to seven months in patients using the standard drug pairing palbociclib and fulvestrant. An estimated 1,000 British women per year could benefit. The combo works for women with a specific breast cancer type called HR+ HER2- with a PIK3CA mutation, which accounts for about three in 10 cases. Professor Kristian Helin, chief of The Institute of Cancer Research in London, said: 'We need to tackle treatment resistance head-on to continue improving survival rates. 'This triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer.' The trial included 325 patients with aggressive and advanced breast cancer from 28 countries. Cancers shrank in two thirds of people receiving the triple drug combination, compared to 28 per cent of those on standard treatment. New go-to option for docs Study author Professor Nicholas Turner, of the Royal Marsden NHS hospital in London, said: 'This therapy not only helped patients live longer but it more than doubled the time before their cancer progressed or worsened. 'It also gave them more time before needing chemotherapy which is something that patients really fear and want to delay for as long as possible.' 'These results give us confidence that this treatment could become the new go-to option.' The study was presented at the conference of the American Society of Clinical Oncology. What are the signs of breast cancer? BREAST cancer is the most common type of cancer in the UK. The majority of women who get it are over 50, but younger women and, in rare cases, men can also get breast cancer. If it's treated early enough, breast cancer can be prevented from spreading to other parts of the body. Breast cancer can have a number of symptoms, but the first noticeable symptom is usually a lump or area of thickened breast tissue. Most breast lumps aren't cancerous, but it's always best to have them checked by your doctor. You should also speak to your GP if you notice any of the following: a change in the size or shape of one or both breasts discharge from either of your nipples (which may be streaked with blood) a lump or swelling in either of your armpits dimpling on the skin of your breasts a rash on or around your nipple a change in the appearance of your nipple, such as becoming sunken into your breast Source: NHS
Scottish Sun
9 hours ago
- Scottish Sun
Three-drug treatment combo ‘holds back aggressive breast cancer for a year'
The treatment could benefit thousands of British women Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) A NEW triple threat drug combination could hold aggressive breast cancer at bay for an extra year, a trial found. Adding the medicine inavolisib to an already used pair of drugs delayed the need for chemotherapy by almost two years. Sign up for Scottish Sun newsletter Sign up 1 Breast cancer gets harder to treat as cells become resistant to drugs (stock image) Credit: Getty It prevented tumours from growing for an average of 17 months, compared to seven months in patients using the standard drug pairing palbociclib and fulvestrant. An estimated 1,000 British women per year could benefit. The combo works for women with a specific breast cancer type called HR+ HER2- with a PIK3CA mutation, which accounts for about three in 10 cases. Professor Kristian Helin, chief of The Institute of Cancer Research in London, said: 'We need to tackle treatment resistance head-on to continue improving survival rates. 'This triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer.' The trial included 325 patients with aggressive and advanced breast cancer from 28 countries. Cancers shrank in two thirds of people receiving the triple drug combination, compared to 28 per cent of those on standard treatment. New go-to option for docs Study author Professor Nicholas Turner, of the Royal Marsden NHS hospital in London, said: 'This therapy not only helped patients live longer but it more than doubled the time before their cancer progressed or worsened. 'It also gave them more time before needing chemotherapy which is something that patients really fear and want to delay for as long as possible.' 'These results give us confidence that this treatment could become the new go-to option.' The study was presented at the conference of the American Society of Clinical Oncology. Breast cancer symptoms you should NEVER ignore, with Dr Philippa Kaye
